PharmaCyte Biotech, Inc. (PMCB): Share Repurchases

Annual figures by period end, from SEC filings.

$401.6K

Year ended 2026-04-30

-69.1%

3-year compound annual growth

2022-04-30 Share Repurchases (USD) 2026-04-30

Period ended	Share Repurchases	Change YoY	Source filing
2026-04-30	$401.6K	-84.2%	2026-07-29, From 2025-05-01
2025-04-30	$2.54M	-91.0%	2026-07-29, From 2024-05-01
2024-04-30	$28.20M	+107.9%	2025-08-11, From 2023-05-01
2023-04-30	$13.56M	n/a	2024-08-13, From 2022-05-01
2022-04-30	$0	n/a	2023-07-31, From 2021-05-01

Share Repurchases at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Share Repurchases	Change YoY
PharmaCyte Biotech, Inc. (PMCB)	2026-04-30	$401.6K	-84.2%
Amgen Inc (AMGN)	2025-12-31	$0	-100.0%
Repligen Corp (RGEN)	2025-12-31	$0	n/a
Champions Oncology, Inc. (CSBR)	2025-04-30	$0	-100.0%
Bio-Techne Corp (TECH)	2026-06-30	$41.67M	-84.9%
Gilead Sciences, Inc. (GILD)	2025-12-31	$1.92B	+67.1%
Neurocrine Biosciences Inc (NBIX)	2025-12-31	$167.70M	-44.1%
Exelixis, Inc. (EXEL)	2026-01-02	$947.51M	+45.3%
Qiagen N.V. (QGEN)	2025-12-31	$280.09M	-4.1%

Compare PMCB, AMGN, RGEN, CSBR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗